Moderna remains a significant player in the EU mRNA Vaccine landscape, especially with the EU regulator backing their updated COVID vaccine. Despite the stock being down 74% over the past year, their strategic positioning and long-term growth potential remain attractive to investors.
Regulatory tailwinds and recent positive efficacy results from the
mRNA flu vaccine trial offer reasons for optimism. In comparative studies,
Moderna's mRNA-1083 has shown promising results against
Pfizer's dual-target mRNA vaccines for influenza and COVID-19. However, there are challenges, like the cancelled contract with the U.S. to develop a Bird Flu Vaccine and their scrapped plan for an mRNA plant in Japan. More recently, Moderna has moved forward with its updated Spikevax vaccine in Europe and demonstrated the potential of its mRNA-based flu vaccine in pivotal studies. Moreover,
Moderna and
IBM are exploring quantum computing for modelling mRNA structure, taking us a step closer to next-gen vaccine development.
Moderna MRNA News Analytics from Thu, 05 Sep 2024 07:00:00 GMT to Sat, 26 Jul 2025 19:49:09 GMT -
Rating 2
- Innovation 7
- Information 8
- Rumor 6
